What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease? - Wikidata - awgldk - TriplyDB

What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?

What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?

http://www.wikidata.org/entity/Q37937555

about

Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD.Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197.Nonhuman targets in allergic lung conditions.Neutrophils and emerging targets for treatment in chronic obstructive pulmonary disease.p38 MAPK inhibitors: a patent review (2012 - 2013).Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease.Inhalation by design.Respivert's multikinase inhibitors, an evaluation of WO2014033446 to WO2014033449.

P2860

Q36146801-DABA9592-1FCF-482D-B0ED-B98EB76D7890 Q36595924-35583145-A069-4EF8-9BE2-87229F3BBDAE Q38077545-7F9235A7-F72B-4FBE-A072-C82764EEF31D Q38156225-6D8DDB49-F5B8-4EFE-9B76-DD7932C97915 Q38194600-ADB3E8D0-A665-45B5-B16B-51A9DD7FFCEC Q38882099-8146FC24-9C69-4262-AAB1-554CDDACCB0F Q51676366-67198E5B-B1C0-4418-9EF8-CC7DD9E7932D Q54309065-394EB2C1-86AF-4437-B199-BF3A0B28B0CA

P2860

What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?

http://www.wikidata.org/entity/Q37937555

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

What is the potential for inha ...... obstructive pulmonary disease?

@en

What is the potential for inha ...... obstructive pulmonary disease?

@nl

type

label

What is the potential for inha ...... obstructive pulmonary disease?

@en

What is the potential for inha ...... obstructive pulmonary disease?

@nl

prefLabel

What is the potential for inha ...... obstructive pulmonary disease?

@en

What is the potential for inha ...... obstructive pulmonary disease?

@nl

P1433

Q37937555-BE0DB3FE-1570-4AF8-B958-41580DA3B632

P1476

Q37937555-0DF45DD4-59F9-4C15-9F3A-E9DDFBF21400

P2093

Q37937555-38E4DA45-311D-4761-B170-DC865519265E

P2860

Q37937555-020A26CC-0583-420D-81A4-BEBEC438D81E

Q37937555-035421CB-B560-4773-970C-81DFB717E1C9

Q37937555-068F750A-7073-492E-A8A1-7D3E550020B5

Q37937555-0EC03717-8B07-4175-8401-D90C399E08D3

Q37937555-0F554476-E182-4600-9ADA-CB18C170909C

Q37937555-11229543-6E59-48B0-A3F4-494B636F9987

Q37937555-13EBE66C-557F-4417-8A96-942973550D34

Q37937555-1F44CC71-6886-4A9D-AD4D-20C6827DB4B8

Q37937555-2A02A021-C582-4182-9932-53538D6923FD

Q37937555-3A1E7092-8F7C-4762-873C-4D25E0DD62E5

P304

Q37937555-A56D27C4-D810-40BE-B19E-995E68C71BBC

P31

Q37937555-EF8E009E-3A9C-48A6-9A09-F232A4BE1C76

P356

Q37937555-07C37785-48D7-4FFE-99CB-4FE3FBB30B04

P433

Q37937555-D21FA6FA-6E04-4F3E-8EC4-916C319E102A

P478

Q37937555-AD950D77-8FB8-4899-A0B0-29768C4BA264

P577

Q37937555-82B807E2-85E8-491E-8CB9-A1793E29CE0C

P698

Q37937555-EE2D52CA-A036-4322-8427-1F706D551633

P921

Q37937555-E4125010-7A25-4028-AD36-A6E82A0A875D

P356

P1433

Future Medicinal Chemistry

P1476

What is the potential for inha ...... obstructive pulmonary disease?

@en

P2093

David S Millan

http://www.w3.org/2001/XMLSchema#string

P2860

Apoptotic cell thrombospondin-1 and heparin-binding domain lead to dendritic-cell phagocytic and tolerizing states

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler

Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs.

Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.

Property-based design: optimization of drug absorption and pharmacokinetics.

The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism.

Pharmacological treatment of established rheumatoid arthritis.

Property-based design of KDR kinase inhibitors.

Systemic delivery of drugs to humans via inhalation.

P304

1635-1645

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/FMC.11.96

http://www.w3.org/2001/XMLSchema#string

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21942253

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease